Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

[1]  A. Mackensen,et al.  Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro , 2006, International journal of cancer.

[2]  L. Platanias,et al.  The PI3' kinase pathway in interferon signaling. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[3]  J. Cheville,et al.  B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. , 2005, Urology.

[4]  M. Berger,et al.  mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.

[5]  V. Kindler,et al.  B7-homolog 1 expression by human glioma: a new mechanism of immune evasion , 2005, Neuroreport.

[6]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[7]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[8]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[9]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[10]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[11]  S. Nelson,et al.  DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.

[12]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[13]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[14]  G. Freeman,et al.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Bigner,et al.  Development of novel targeted therapies in the treatment of malignant glioma , 2004, Nature Reviews Drug Discovery.

[16]  B. Quesnel,et al.  In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. , 2004, Blood.

[17]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[18]  J. Cheville,et al.  Costimulatory B 7-H 1 in renal cell carcinoma patients : Indicator of tumor aggressiveness and potential therapeutic target , 2004 .

[19]  M. Weller,et al.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.

[20]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[21]  M. Sulis,et al.  PTEN: from pathology to biology. , 2003, Trends in cell biology.

[22]  Lieping Chen,et al.  B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.

[23]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[24]  G. Zhu,et al.  Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. , 2003, The Journal of clinical investigation.

[25]  M. Weller,et al.  Expression of the B 7-Related Molecule B 7-H 1 by Glioma Cells : A Potential Mechanism of Immune Paralysis 1 , 2003 .

[26]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[27]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[28]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[29]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[30]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[31]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[32]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  Gordon Mills,et al.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC , 1998, Current Biology.